Literature DB >> 21528082

Gastric cancer cells induce human CD4+Foxp3+ regulatory T cells through the production of TGF-β1.

Xiang-Liang Yuan1, Lei Chen, Tong-Tong Zhang, Yan-Hui Ma, Yun-Lan Zhou, Yan Zhao, Wei-Wei Wang, Ping Dong, Liang Yu, Yan-Yun Zhang, Li-Song Shen.   

Abstract

AIM: To elucidate the molecular and cellular features responsible for the increase of regulatory T cells (Tregs) in gastric cancer.
METHODS: The frequencies of CD4(+)Foxp3(+) Tregs and the level of transforming growth factor-β1 (TGF-β1) were analyzed from 56 patients with gastric cancer by flow cytometry and enzyme-linked immunosorbent assay respectively. Foxp3 gene expression was analyzed by real-time polymerase chain reaction. The gastric cancer microenvironment was modeled by establishing the co-culture of gastric cancer cell line, MGC-803, with sorting CD4(+) T cells. The normal gastric mucosa cell line, GES-1, was used as the control. The production of TGF-β1 was detected in supernatant of MGC and GES-1. The carboxyfluorescein diacetatesuccinimidyl ester (CFSE) dilution assay was performed to evaluate the proliferation characteristics of induced Tregs. Neutralizing anti-TGF-β1 antibody was added to the co-culture system for neutralization experiments.
RESULTS: The level of serum TGF-β1 in gastric cancer patients (15.1 ± 5.5 ng/mL) was significantly higher than that of the gender- and age-matched healthy controls (10.3 ± 3.4 ng/mL) (P < 0.05). Furthermore, the higher TGF-β1 level correlated with the increased population of CD4(+)Foxp3(+) Tregs in advanced gastric cancer (r = 0.576, P < 0.05). A significant higher frequency of CD4(+)Foxp3(+) Tregs was observed in PBMCs cultured with the supernatant of MGC than GES-1 (10.6% ± 0.6% vs 8.7% ± 0.7%, P < 0.05). Moreover, using the purified CD4(+)CD25(-) T cells, we confirmed that the increased Tregs were mainly induced from the conversation of CD4(+)CD25(-) naive T cells, and induced Tregs were functional and able to suppress the proliferation of effector T cells. Finally, we demonstrated that gastric cancer cells induced the increased CD4(+)Foxp3(+) Tregs via producing TGF-β1. Gastric cancer cells upregulated the production of TGF-β1 and blockade of TGF-β1 partly abrogated Tregs phenotype.
CONCLUSION: Gastric cancer cell can induce Tregs development via producing TGF-β1, by which the existence of cross-talk between the tumor and immune cells might regulate anti-tumor immune responses.

Entities:  

Keywords:  Gastric cancer; Immune suppression; Regulatory T cells; Transforming growth factor-β1

Mesh:

Substances:

Year:  2011        PMID: 21528082      PMCID: PMC3082757          DOI: 10.3748/wjg.v17.i15.2019

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation.

Authors:  Thorsten R Mempel; Mikael J Pittet; Khashayarsha Khazaie; Wolfgang Weninger; Ralph Weissleder; Harald von Boehmer; Ulrich H von Andrian
Journal:  Immunity       Date:  2006-07       Impact factor: 31.745

2.  Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms.

Authors:  Ming O Li; Shomyseh Sanjabi; Richard A Flavell
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

3.  Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.

Authors:  Dat Q Tran; Heather Ramsey; Ethan M Shevach
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

4.  TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival.

Authors:  Konstantinos Vagenas; Charalambos Spyropoulos; Vasiliki Gavala; Athanassios C Tsamandas
Journal:  J Surg Res       Date:  2007-01-30       Impact factor: 2.192

5.  Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells.

Authors:  Mengde Cao; Roniel Cabrera; Yiling Xu; Roberto Firpi; Haizhen Zhu; Chen Liu; David R Nelson
Journal:  Lab Invest       Date:  2007-03-19       Impact factor: 5.662

6.  Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer.

Authors:  Yingsong Lin; Shogo Kikuchi; Yuki Obata; Kiyoko Yagyu
Journal:  J Gastroenterol Hepatol       Date:  2006-02       Impact factor: 4.029

Review 7.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

Review 8.  Transforming growth factor-beta and the immune response: implications for anticancer therapy.

Authors:  Stephen H Wrzesinski; Yisong Y Wan; Richard A Flavell
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 9.  Epidemiology of gastric cancer.

Authors:  Katherine D Crew; Alfred I Neugut
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

10.  Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients.

Authors:  L J A C Hawinkels; H W Verspaget; W van Duijn; J M van der Zon; K Zuidwijk; F J G M Kubben; J H Verheijen; D W Hommes; C B H W Lamers; C F M Sier
Journal:  Br J Cancer       Date:  2007-07-17       Impact factor: 7.640

View more
  21 in total

1.  Association between gastric cancer and -1993 polymorphism of TBX21 gene.

Authors:  Le-Hui Zhang; Qin Li; Peng Li; Sheng-Tao Zhu; Jing Wang; Hong-Li Yang; Chang-Qing Xu; Xiu-Hua Guo
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

2.  Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer.

Authors:  Tao Liu; Liusheng Peng; Peiwu Yu; Yongliang Zhao; Yun Shi; Xuhu Mao; Weisan Chen; Ping Cheng; Tingting Wang; Na Chen; Jinyu Zhang; Xiaofei Liu; Na Li; Gang Guo; Wende Tong; Yuan Zhuang; Quanming Zou
Journal:  J Clin Immunol       Date:  2012-07-04       Impact factor: 8.317

Review 3.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

Review 4.  The immune microenvironment in gastric adenocarcinoma.

Authors:  Yana Zavros; Juanita L Merchant
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-03-14       Impact factor: 73.082

5.  Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period?

Authors:  Li Jiang; Alpa M Nick; Anil K Sood
Journal:  Curr Anesthesiol Rep       Date:  2015-09

6.  Increased numbers of gastric-infiltrating mast cells and regulatory T cells are associated with tumor stage in gastric adenocarcinoma patients.

Authors:  Yibin Zhao; Ke Wu; Kailin Cai; Ronglin Zhai; Kaixiong Tao; Guobin Wang; Jiliang Wang
Journal:  Oncol Lett       Date:  2012-07-27       Impact factor: 2.967

7.  Malignant B cells induce the conversion of CD4+CD25- T cells to regulatory T cells in B-cell non-Hodgkin lymphoma.

Authors:  Yixiang Han; Jianbo Wu; Laixi Bi; Shudao Xiong; Shenmeng Gao; Lihui Yin; Lei Jiang; Chiqi Chen; Kang Yu; Shenghui Zhang
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

Review 8.  T cells in gastric cancer: friends or foes.

Authors:  Amedeo Amedei; Chiara Della Bella; Elena Silvestri; Domenico Prisco; Mario M D'Elios
Journal:  Clin Dev Immunol       Date:  2012-05-31

9.  Determining the effect of transforming growth factor-β1 on cdk4 and p27 in gastric cancer and cholangiocarcinoma.

Authors:  Sung Ryol Lee; Jae Wook Shin; Hyung Ook Kim; Byung Ho Son; Chang Hak Yoo; Jun Ho Shin
Journal:  Oncol Lett       Date:  2012-11-13       Impact factor: 2.967

10.  Influence of tumors on protective anti-tumor immunity and the effects of irradiation.

Authors:  Gemma A Foulds; Jürgen Radons; Mira Kreuzer; Gabriele Multhoff; Alan G Pockley
Journal:  Front Oncol       Date:  2013-02-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.